Progress in the development of human parainfluenza virus vaccines

Alexander C. Schmidt; Anne Schaap-Nutt; Emmalene J. Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A. Karron; Peter L. Collins

doi:10.1586/ers.11.32

Progress in the development of human parainfluenza virus vaccines

Alexander C. Schmidt
, Anne Schaap-Nutt
, Emmalene J. Bartlett
, Henrick Schomacker
, Jim Boonyaratanakornkit
, Ruth A. Karron
, Peter L. Collins

Bloomberg School of Public Health

Research output: Contribution to journal › Review article › peer-review

66 Scopus citations

Abstract

In children under 5 years of age, human parainfluenza viruses (HPIVs) as a group are the second most common etiology of acute respiratory illness leading to hospitalization, surpassed only by respiratory syncytial virus but ahead of influenza viruses. Using reverse genetics systems for HPIV serotypes 1, 2 and 3 (HPIV1, 2 and 3), several live-attenuated HPIVs have been generated and evaluated as intranasal vaccines in adults and in children. Two vaccines against HPIV3 were found to be well tolerated, infectious and immunogenic in Phase I trials in HPIV3-seronegative infants and children and should progress to proof-of-concept trials. Vaccines against HPIV1 and HPIV2 are less advanced and have just entered pediatric trials.

Original language	English (US)
Pages (from-to)	515-526
Number of pages	12
Journal	Expert Review of Respiratory Medicine
Volume	5
Issue number	4
DOIs	https://doi.org/10.1586/ers.11.32
State	Published - Aug 2011

Keywords

acute respiratory illness
clinical trial
intranasal
live-attenuated
parainfluenza virus vaccine
pediatric
vaccine

ASJC Scopus subject areas

Immunology and Allergy
Pulmonary and Respiratory Medicine
Public Health, Environmental and Occupational Health

Access to Document

10.1586/ers.11.32

Cite this

@article{fdb70ec3e84c4a7b82c05f3a738e6ca5,

title = "Progress in the development of human parainfluenza virus vaccines",

abstract = "In children under 5 years of age, human parainfluenza viruses (HPIVs) as a group are the second most common etiology of acute respiratory illness leading to hospitalization, surpassed only by respiratory syncytial virus but ahead of influenza viruses. Using reverse genetics systems for HPIV serotypes 1, 2 and 3 (HPIV1, 2 and 3), several live-attenuated HPIVs have been generated and evaluated as intranasal vaccines in adults and in children. Two vaccines against HPIV3 were found to be well tolerated, infectious and immunogenic in Phase I trials in HPIV3-seronegative infants and children and should progress to proof-of-concept trials. Vaccines against HPIV1 and HPIV2 are less advanced and have just entered pediatric trials.",

keywords = "acute respiratory illness, clinical trial, intranasal, live-attenuated, parainfluenza virus vaccine, pediatric, vaccine",

author = "Schmidt, \{Alexander C.\} and Anne Schaap-Nutt and Bartlett, \{Emmalene J.\} and Henrick Schomacker and Jim Boonyaratanakornkit and Karron, \{Ruth A.\} and Collins, \{Peter L.\}",

note = "Funding Information: Many of the studies reviewed here were supported by the Intramural Research Program of the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health. NIAID-sponsored clinical trials were conducted as part of research contracts between NIAID and the Johns Hopkins Bloomberg School of Public Health (JHSPH). We would like to thank all of the clinical research teams for their excellent work. Since 2006, NIAID and MedImmune have a collaborative research and development agreement for the development of RSV, HPIV and HMPV vaccines in place. We are grateful to be part of this collaboration. Brian Murphy led the PIV vaccine development program until 2010 and we appreciate his leadership and support. Sonja Surman was instrumental in generating vaccine seed viruses and Mario Skiadopoulos oversaw the preclinical research and development of a many PIV vaccine candidates. Finally, we would like to thank the many individuals and families who participated in the investigational vaccine studies reviewed here.",

year = "2011",

month = aug,

doi = "10.1586/ers.11.32",

language = "English (US)",

volume = "5",

pages = "515--526",

journal = "Expert Review of Respiratory Medicine",

issn = "1747-6348",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Progress in the development of human parainfluenza virus vaccines

AU - Schmidt, Alexander C.

AU - Schaap-Nutt, Anne

AU - Bartlett, Emmalene J.

AU - Schomacker, Henrick

AU - Boonyaratanakornkit, Jim

AU - Karron, Ruth A.

AU - Collins, Peter L.

N1 - Funding Information: Many of the studies reviewed here were supported by the Intramural Research Program of the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health. NIAID-sponsored clinical trials were conducted as part of research contracts between NIAID and the Johns Hopkins Bloomberg School of Public Health (JHSPH). We would like to thank all of the clinical research teams for their excellent work. Since 2006, NIAID and MedImmune have a collaborative research and development agreement for the development of RSV, HPIV and HMPV vaccines in place. We are grateful to be part of this collaboration. Brian Murphy led the PIV vaccine development program until 2010 and we appreciate his leadership and support. Sonja Surman was instrumental in generating vaccine seed viruses and Mario Skiadopoulos oversaw the preclinical research and development of a many PIV vaccine candidates. Finally, we would like to thank the many individuals and families who participated in the investigational vaccine studies reviewed here.

PY - 2011/8

Y1 - 2011/8

N2 - In children under 5 years of age, human parainfluenza viruses (HPIVs) as a group are the second most common etiology of acute respiratory illness leading to hospitalization, surpassed only by respiratory syncytial virus but ahead of influenza viruses. Using reverse genetics systems for HPIV serotypes 1, 2 and 3 (HPIV1, 2 and 3), several live-attenuated HPIVs have been generated and evaluated as intranasal vaccines in adults and in children. Two vaccines against HPIV3 were found to be well tolerated, infectious and immunogenic in Phase I trials in HPIV3-seronegative infants and children and should progress to proof-of-concept trials. Vaccines against HPIV1 and HPIV2 are less advanced and have just entered pediatric trials.

AB - In children under 5 years of age, human parainfluenza viruses (HPIVs) as a group are the second most common etiology of acute respiratory illness leading to hospitalization, surpassed only by respiratory syncytial virus but ahead of influenza viruses. Using reverse genetics systems for HPIV serotypes 1, 2 and 3 (HPIV1, 2 and 3), several live-attenuated HPIVs have been generated and evaluated as intranasal vaccines in adults and in children. Two vaccines against HPIV3 were found to be well tolerated, infectious and immunogenic in Phase I trials in HPIV3-seronegative infants and children and should progress to proof-of-concept trials. Vaccines against HPIV1 and HPIV2 are less advanced and have just entered pediatric trials.

KW - acute respiratory illness

KW - clinical trial

KW - intranasal

KW - live-attenuated

KW - parainfluenza virus vaccine

KW - pediatric

KW - vaccine

UR - https://www.scopus.com/pages/publications/80052620543

UR - https://www.scopus.com/pages/publications/80052620543#tab=citedBy

U2 - 10.1586/ers.11.32

DO - 10.1586/ers.11.32

M3 - Review article

C2 - 21859271

AN - SCOPUS:80052620543

SN - 1747-6348

VL - 5

SP - 515

EP - 526

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

IS - 4

ER -

Progress in the development of human parainfluenza virus vaccines

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this